Showing results (111-120 of 136) with videos related to
Sort By:
Pageof 14
Molecular Pharmacology|July 19, 2003
Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell killPaul W Schenk, Mariel Brok, Antonius W M Boersma, et al.Cancer Chemotherapy and Pharmacology|March 18, 2006
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumorsA Felici, W J Loos, J Verweij, et al.Cancer Research|April 10, 1999
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implicationsA Sparreboom, L van Zuylen, E Brouwer, et al.Leukemia|July 1, 1993
High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotypeP Sonneveld, J J van Dongen, A Hagemeijer, et al.Human Gene Therapy|June 20, 1996
Frequency analysis of multidrug resistance-1 gene transfer into human primitive hematopoietic progenitor cells using the cobblestone area-forming cell assay and detection of vector-mediated P-glycoprotein expression by rhodamine-123S Fruehauf, D A Breems, S Knaän-Shanzer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2001
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposureF E de Jongh, J Verweij, W J Loos, et al.Anti-Cancer Drugs|August 21, 2002
Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxelWalter J Loos, Janos Szebeni, Albert J ten Tije, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2006
Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area valuesWalter J Loos, Felix E de Jongh, Alex Sparreboom, et al.Cancer Biology & Therapy|June 23, 2005
Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumpsHerman Burger, Hans van Tol, Mariël Brok, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic responseHerman Burger, John A Foekens, Maxime P Look, et al.Pageof 14